The first and only approved anti-amyloid Alzheimer's Disease (AD) treatment shown to reduce the rate of disease progression and slow cognitive impairment has been granted approval by the FDA.
With Eisai and Biogen’s Alzheimer’s drug Leqembi (lecanemab) approved by the US Food and Drug Administration (FDA) last week, Eisai has revealed more details on its rollout plans for the drug.
An investigational Alzheimer's drug made by Eisai Co Ltd and Biogen slowed cognitive and functional decline in a trial involving a large group of patients in the early stages of the disease.
In a simulation model, lecanemab treatment was estimated to potentially slow the rate of disease progression, maintaining treated patients for a longer duration in earlier stages of mild cognitive impairment (MCI) due to early AD.
Biogen and its partner, Eisai, confirm a decision to stop the Phase III development of aducanumab, a potential treatment for Alzheimer’s – a key part of the former’s pipeline.